… antifibrotic therapy for idiopathic pulmonary fibrosis (IPF). We aimed to assess the course
of disease of IPF patients with and without antifibrotic therapy … enrolled IPF patients from 20 …

… There is an urgent need to identify effective antifibrotic agents for IPF. In this review, evolving
concepts in IPF pathogenesis and emerging therapeutic targets for this lethal lung disease …

… , may influence the course of IPF through its anti-inflammatory and antifibrotic effects. In
this study, bosentan treatment in patients with IPF did not show superiority over placebo on …

… of our study was antifibrotic therapy in an elderly IPF cohort. … In the present analysis of
INSIGHTS-IPF, which is based on a … and nonelderly patients, antifibrotic therapy was significantly …

… Our results reported lower concentrations of IFN- γ after antifibrotic treatment and no
differences between IPF patients at baseline and healthy controls, in line with Tfh1 distribution. …

… The majority of patients with IPF die from an acute exacerbation or respiratory failure [8, 9]. …
of IPF and the utility of antifibrotic therapies, with a focus on the importance of early treatment. …

… or bilateral in IPF patients, warrants further insight and is an … Antibiotic therapy might therefore
be useful in modifying IPF … IPF patients in conjunction with approved antifibrotic therapy …

… approval for the treatment of mild or moderate IPF in Europe and Japan is pirfenidone, a
pyridone compound with pleiotropic, anti-inflammatory, antifibrotic and antioxidant properties, …

… of therapy during these studies may have introduced bias. This study investigated the
effect of antifibrotic therapy on mortality and other outcomes in patients with IPF using causal …

… additional insights into IPF biology and … IPF, and were published before the use of antifibrotic
therapy was widespread (98). Introduction of disease-stabilizing antifibrotic therapy for IPF, …